These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 14639062)

  • 1. Polymorphisms in the CYP 2D6 gene: association with plasma concentrations of fluoxetine and paroxetine.
    Charlier C; Broly F; Lhermitte M; Pinto E; Ansseau M; Plomteux G
    Ther Drug Monit; 2003 Dec; 25(6):738-42. PubMed ID: 14639062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6.
    Lam YW; Gaedigk A; Ereshefsky L; Alfaro CL; Simpson J
    Pharmacotherapy; 2002 Aug; 22(8):1001-6. PubMed ID: 12173784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytochrome P450 2D6 genotype does not predict SSRI (fluoxetine or paroxetine) induced hyponatraemia.
    Stedman CA; Begg EJ; Kennedy MA; Roberts R; Wilkinson TJ
    Hum Psychopharmacol; 2002 Jun; 17(4):187-90. PubMed ID: 12404686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential for clinically significant drug-drug interactions involving the CYP 2D6 system: effects with fluoxetine and paroxetine versus sertraline.
    Preskorn SH; Shah R; Neff M; Golbeck AL; Choi J
    J Psychiatr Pract; 2007 Jan; 13(1):5-12. PubMed ID: 17242587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine.
    Scordo MG; Spina E; Dahl ML; Gatti G; Perucca E
    Basic Clin Pharmacol Toxicol; 2005 Nov; 97(5):296-301. PubMed ID: 16236141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of cytochrome P450 2D6 genotype on maternal paroxetine plasma concentrations during pregnancy.
    Ververs FF; Voorbij HA; Zwarts P; Belitser SV; Egberts TC; Visser GH; Schobben AF
    Clin Pharmacokinet; 2009; 48(10):677-83. PubMed ID: 19743889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Precision dosing-based optimisation of paroxetine during pregnancy for poor and ultrarapid CYP2D6 metabolisers: a virtual clinical trial pharmacokinetics study.
    Almurjan A; Macfarlane H; Badhan RKS
    J Pharm Pharmacol; 2020 Aug; 72(8):1049-1060. PubMed ID: 32346890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytochrome P450 2D6 genotype affects the pharmacokinetics of controlled-release paroxetine in healthy Chinese subjects: comparison of traditional phenotype and activity score systems.
    Chen R; Wang H; Shi J; Shen K; Hu P
    Eur J Clin Pharmacol; 2015 Jul; 71(7):835-41. PubMed ID: 25967538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine.
    Sawamura K; Suzuki Y; Someya T
    Eur J Clin Pharmacol; 2004 Oct; 60(8):553-7. PubMed ID: 15349705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations.
    Alfaro CL; Lam YW; Simpson J; Ereshefsky L
    J Clin Pharmacol; 2000 Jan; 40(1):58-66. PubMed ID: 10631623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low serum concentrations of paroxetine in CYP2D6 ultrarapid metabolizers.
    Güzey C; Spigset O
    J Clin Psychopharmacol; 2006 Apr; 26(2):211-2. PubMed ID: 16633156
    [No Abstract]   [Full Text] [Related]  

  • 12. Impact of CYP2D6 Genotype on Paroxetine Serum Concentration.
    Hole K; Haslemo T; Molden E
    Ther Drug Monit; 2023 Oct; 45(5):683-688. PubMed ID: 37012633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant use of selective serotonin reuptake inhibitors with other cytochrome P450 2D6 or 3A4 metabolized medications: how often does it really happen?
    Gregor KJ; Way K; Young CH; James SP
    J Affect Disord; 1997 Oct; 46(1):59-67. PubMed ID: 9387087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine.
    Azuma J; Hasunuma T; Kubo M; Miyatake M; Koue T; Higashi K; Fujiwara T; Kitahara S; Katano T; Hara S
    Eur J Clin Pharmacol; 2012 Jan; 68(1):29-37. PubMed ID: 21739267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.
    Ereshefsky L; Riesenman C; Lam YW
    Clin Pharmacokinet; 1995; 29 Suppl 1():10-8; discussion 18-9. PubMed ID: 8846618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic consequences of selective serotonin reuptake inhibitor use with drugs also metabolized by the cytochrome P-450 system.
    Ozminkowski RJ; Hylan TR; Melfi CA; Meneades LM; Crown WH; Croghan TW; Robinson RL
    Clin Ther; 1998; 20(4):780-96. PubMed ID: 9737837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The burden and management of cytochrome P450 2D6 (CYP2D6)-mediated drug-drug interaction (DDI): co-medication of metoprolol and paroxetine or fluoxetine in the elderly.
    Bahar MA; Hak E; Bos JHJ; Borgsteede SD; Wilffert B
    Pharmacoepidemiol Drug Saf; 2017 Jul; 26(7):752-765. PubMed ID: 28345306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-clinical evaluation of CYP 2D6 dependent drug-drug interactions between primaquine and SSRI/SNRI antidepressants.
    Jin X; Potter B; Luong TL; Nelson J; Vuong C; Potter C; Xie L; Zhang J; Zhang P; Sousa J; Li Q; Pybus BS; Kreishman-Deitrick M; Hickman M; Smith PL; Paris R; Reichard G; Marcsisin SR
    Malar J; 2016 May; 15(1):280. PubMed ID: 27188854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome p450 genotypes.
    Berle JØ; Steen VM; Aamo TO; Breilid H; Zahlsen K; Spigset O
    J Clin Psychiatry; 2004 Sep; 65(9):1228-34. PubMed ID: 15367050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reboxetine and cytochrome P450--comparison with paroxetine treatment in humans.
    Kuhn UD; Kirsch M; Merkel U; Eberhardt AM; Wenda B; Maurer I; Härtter S; Hiemke C; Volz HP; Balogh A
    Int J Clin Pharmacol Ther; 2007 Jan; 45(1):36-46. PubMed ID: 17256449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.